CompletedPhase 1NCT03805984
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Studying Lassa fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inovio Pharmaceuticals
- Principal Investigator
- Mammen Mammen, MD, FACP, FIDSAInovio Pharmaceuticals
- Intervention
- INO-4500(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2019 – 2020
Study locations (1)
- The Center for Pharmaceutical Research, Kansas City, Missouri, United States
Collaborators
Coalition for Epidemic Preparedness Innovations
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03805984 on ClinicalTrials.govOther trials for Lassa fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07419373ARN-75039 Lassa Fever Treatment in West AfricaArisan Therapeutics, Inc.
- RECRUITINGPHASE2, PHASE3NCT06212336ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyIrrua Specialist Teaching Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT06546709DMID 23-0015; Lassa Fever CVD 1000Wilbur Chen, MD, MS
- RECRUITINGPHASE2NCT05868733A Lassa Fever Vaccine Trial in Adults and Children Residing in West AfricaInternational AIDS Vaccine Initiative
- RECRUITINGPHASE2NCT06222723LAssa Fever Adjunct Treatment With DEXamethasoneBernhard Nocht Institute for Tropical Medicine
- ACTIVE NOT RECRUITINGNCT03655561Lassa Fever Clinical Course and Prognostic Factors in NigeriaAlliance for International Medical Action